RecruitingPhase 4NCT05441267

A Study of Cardiovascular Events iN Diabetes Plus

Sponsor

University of Oxford

Enrollment

20,000 participants

Start Date

Mar 13, 2023

Study Type

INTERVENTIONAL

Conditions

Diabetes Mellitus, Type 2

Summary

ASCEND PLUS is testing whether, for people with type 2 diabetes who have not previously had a heart attack or stroke, regularly taking a tablet called semaglutide can safely help to reduce heart attacks, strokes, mini-strokes, the need for any procedures to unblock or bypass an artery to their heart, and the chance of dying because of vascular problems.

Eligibility

Min Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying whether a GLP-1 receptor agonist medication (a type of diabetes drug that also protects the heart) reduces the risk of serious cardiovascular events in older adults with type 2 diabetes. You may be eligible if: you are 55 years or older; and you have type 2 diabetes based on your medical history. You may NOT be eligible if: you have had a recent heart attack or stroke; you are already on or planning to start a GLP-1 medication; you have had a severe low blood sugar episode recently; you have severe heart failure; you need dialysis; you have active cancer (except non-melanoma skin cancer); you have type 1 diabetes; or you are pregnant or breastfeeding. Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.